本文選題：急性肝性腦病　切入點(diǎn)：利福昔明　出處：《中國全科醫(yī)學(xué)》2010年33期

【摘要】：正【摘要】背景肝性腦病是肝硬化的慢性衰竭并發(fā)癥。利福昔明屬吸收量極微的抗生素,其治療急性肝性腦病有良好的證據(jù),但其預(yù)防疾病的效果尚未確定。方法隨機(jī)、雙盲、安慰劑對(duì)照試驗(yàn),將299例因慢性肝病導(dǎo)致肝性腦病反復(fù)發(fā)作的患者隨機(jī)分組:利福昔明組140例,接
[Abstract]:Background Hepatic encephalopathy is a complication of chronic failure of liver cirrhosis. Rifaximin is an antibiotic with minimal absorption and has good evidence for the treatment of acute hepatic encephalopathy. In a placebo controlled trial, 299 patients with recurrent hepatic encephalopathy due to chronic liver disease were randomly divided into two groups: rifaximin group, 140 patients, followed by
【作者單位】： 中國石油中心醫(yī)院;
【分類號(hào)】：R747.9
，

本文編號(hào)：1671305